Death knell sounds for CB1 antagonists

Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. [C#198601345:Sanofi-Aventis] is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and [C#198600199:Pfizer]is discontinuing its Phase III candidate CP-945,598.